Sign in Subscribe
Pharmaceutical industry

ImmunoGen Receives $750,000 SBIR Grant to Develop Targeted Cancer Therapies

Strategic Insights

— 1 min read

ImmunoGen, Inc., a biopharmaceutical company focused on cancer treatment, has been awarded a $750,000 Phase II Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI) to develop targeted small-molecule drugs for cancer treatment. The grant will fund the company's research on immunoconjugates, a class of small-drug compounds that attach to specific cancer cells, interfering with their function and causing cell death. ImmunoGen's research has shown promising results in preclinical testing, with its immunoconjugates demonstrating high potency and specificity in targeting cancer cells. The company plans to complete preclinical testing of its first humanized antibody/small-drug immunoconjugate product candidates over the next two years, with the aim of starting human clinical trials.

Key Takeaways:

  • ImmunoGen has received a $750,000 Phase II SBIR grant from the NCI to develop targeted small-molecule drugs for cancer treatment.
  • The grant will fund research on immunoconjugates, a class of small-drug compounds that attach to specific cancer cells, interfering with their function and causing cell death.
  • ImmunoGen's research has shown promising results in preclinical testing, with its immunoconjugates demonstrating high potency and specificity in targeting cancer cells.
  • The company plans to complete preclinical testing of its first humanized antibody/small-drug immunoconjugate product candidates over the next two years, with the aim of starting human clinical trials.
  • ImmunoGen's lead product, Oncolysin(R) B, is currently in Phase III clinical testing for the treatment of B-cell malignancies.
  • The company has humanized two monoclonal antibodies, one targeting B-cell malignancies and another targeting small-cell lung cancer.

Sources:

  • "Phase II SBIR Grant Awarded to Develop ImmunoGen's CAMBRIDGE, Mass., June 6 /PRNewswire/ --" (Source: PRNewswire)
  • National Cancer Institute (NCI) of the National Institutes of Health
  • U.S. Food and Drug Administration

Read more